News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

That Model Genentech (RHHBY), Gilead Sciences, Inc. (GILD), And Amgen (AMGN) Were Built On—Does It Work Anymore?


7/16/2014 6:15:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

“The model is broken.”

I used to hear that chant from biotech VCs all the time, often accompanied by the thwack of self-flagellation. The model was supposed to work like this: put money into highly risky science, nurture it, and wait a long time—sometimes five years, usually a lot longer—for that risk to become an unlikely reward. Most efforts would fail, but a few home runs would propel the investors to the next fund. That model built Genentech, Amgen (NASDAQ: AMGN), Gilead Sciences (NASDAQ: GILD), Regeneron Pharmaceuticals (NASDAQ: REGN), and so many others.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Xconomy

comments powered by Disqus
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES